Fremont, CA, June 05, 2010 --(PR.com
)-- Rhodamine 110 (Rh110)-labeled peptides are used in the study of a number of protease activity, such as cysteine aspartate-specific proteases and serine proteases.1-2 Rhodamine 110 contains two amino groups available for conjugation to the C-terminal end of a peptide or amino acid. Protease cleavage of the non-fluorescent bis-substituted rhodamine 110 peptide derivatives result in monosubstituted rhodamine 110 and free rhodamine 110, both of which are fluorescent.1 Fluorescence intensity can therefore be correlated to protease activity.
Rhodamine110 conjugated to charged amino acids are generally cell permeable. As a results, these substrates can be used in intact cells for applications such as flow cytometry.2 Rhodamine labeled peptides affords significant advantages over AFC or AMC labeled peptides in that Rh110 emits in the green range (Ex/Em=501/527nm), while AMC (Ex/Em=340/440 nm) and AFC (Ex/Em=370/500 nm) emits in the blue range. Autofluorescence interference from cellular components is minimal, making the substrates more sensitive. Rhodamine 110-peptide conjugates are also not pH dependent.1
Rothe, G. et al. Biol. Chem. Hoppe-Seyler 373, 547 (1992).
Hug, H. et al. Biochem. 38, 13906 (1999).
AnaSpec is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and antibodies.
AnaSpec recently joined forces with Eurogentec to provide an even broader spectrum of products and services to serve the worldwide life science community.
For more information visit www.anaspec.com
Eurogentec is a leading global supplier of innovative reagents, kits, specialty products and custom services to scientists in the life science, biotechnology, pharmaceutical and diagnostic markets. Eurogentec provides a wide range of expertize in small- and large-scale DNA, RNA, PCR and qPCR kits, peptide synthesis and antibody supply for research applications. Our ISO13485:2003-certified manufacturing facilities in Belgium provides a wide range of high value oligonucleotide-based components for diagnostic and therapeutic applications. Eurogentec’s Belgium manufacturing facility is complemented by additional production facilities in North America and Japan. Eurogentec is also an experienced Contract Manufacturing Organization (CMO) for Biopharmaceuticals, operating a full-service, state-of-the-art GMP facility in Belgium.
Eurogentec is a privately held company headquartered in Liège, Belgium, with subsidiaries in North America, France, Germany, the UK, the Netherlands and Switzerland and has additional production facilities in North America, Japan and Singapore. Eurogentec employs 400+ people globally.
For more information visit www.eurogentec.com